(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vacuum Cleaners That Are Not difficult To Use For Home - 2Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- 3Picking Childcare Administrations for Your Loved ones
- 4'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
- 5Cocoa Prices Settle Lower on Expectations of Adequate Supplies
- Figure out How to Assess the Unwavering quality of SUVs for Seniors
- How grandchildren are stepping up to fill the caregiver gap
- Figure out How to Take part in Open Conversations Around 5G Pinnacles
- Monetary Wellness: Planning Tips for Independence from the rat race
- Bomb blast in packed Nigerian mosque kills five
- 5 Pizza Fixings That Characterize Your Character
- Finding Europe's Head Traveler Objections: An Excursion Through Famous Attractions
- Figure out How to Protect Your Gold Venture from Unpredictability
- What’s the shadowy organisation taking Gaza Palestinians to South Africa?
